Gilteritinib

Resumen

Alternativas con registro en Colombia

• Sunitinib · costo anual estimado $ 71.107.110
• Sorafenib · costo anual estimado $ 106.496.050
• Pazopanib · costo anual estimado $ 77.475.995
• Regorafenib · costo anual estimado $ 261.973.275
• Cabozantinib · costo anual estimado $ 837.269.485
• Lenvatinib · costo anual estimado $ 269.626.960
• Nintedanib · costo anual estimado $ 98.785.790
• Midostaurina · costo anual estimado $ 588.977.870
• Larotrectinib
• Entrectinib · costo anual estimado $ 246.138.480
• Selpercatinib · costo anual estimado $ 387.094.545

Estudios clínicos principales

• A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FL
  Fase 3 · 2017 · 356 participantes · Astellas Pharma Global Development, Inc. · NCT02997202
• A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed
  Fase 3 · 2016 · 183 participantes · Astellas Pharma Global Development, Inc. · NCT02752035
• A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutatio
  Fase 3 · 2015 · 371 participantes · Astellas Pharma Global Development, Inc. · NCT02421939
• A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutat
  Fase 3 · 2017 · 276 participantes · Astellas Pharma Inc · NCT03182244

Enfermedades relacionadas

• Cáncer (todos)
• Leucemias

Fuentes

• EMA: Xospata